Understanding Research Methods: Up-and-down Designs for Dose-finding

被引:35
|
作者
Oron, Assaf P. [1 ]
Souter, Michael J. [2 ,3 ,4 ]
Flournoy, Nancy [5 ]
机构
[1] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA
[2] Univ Washington, Anesthesia Serv, Harborview Med Ctr, Seattle, WA 98195 USA
[3] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA USA
[4] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA
[5] Univ Missouri, Dept Stat, Columbia, MO 65211 USA
关键词
SMALL-SAMPLE BEHAVIOR; SEQUENTIAL ALLOCATION; STAIRCASE METHOD; ROPIVACAINE; TRIAL; BLOCK; ED50; ED95; LEVOBUPIVACAINE; SEVOFLURANE;
D O I
10.1097/ALN.0000000000004282
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
For the task of estimating a target benchmark dose such as the ED50 (the dose that would be effective for half the population), an adaptive dose-finding design is more effective than the standard approach of treating equal numbers of patients at a set of equally spaced doses. Up-and-down is the most popular family of dose-finding designs and is in common use in anesthesiology. Despite its widespread use, many aspects of up-and-down are not well known, implementation is often misguided, and standard, up-to-date reference material about the design is very limited. This article provides an overview of up-and- down properties, recent methodologic developments, and practical recommendations, illustrated with the help of simulated examples. Additional reference material is offered in the Supplemental Digital Content.
引用
收藏
页码:137 / 150
页数:14
相关论文
共 50 条
  • [31] Adaptive designs for Phase I dose-finding studies
    Zhou, Yinghui
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 (02) : 129 - 138
  • [32] Adapting Pharmacological Dose-Finding Designs for Early Phase Behavioral Intervention Development Research
    Towner, Elizabeth Kuhl
    Carcone, April Idalski
    Ghosh, Samiran
    Ondersma, Steven
    Stylianou, Mario
    HEALTH PSYCHOLOGY, 2021, 40 (12) : 875 - 880
  • [33] Dose-finding designs for trials of molecularly targeted agents and immunotherapies
    Chiuzan, Cody
    Shtaynberger, Jonathan
    Manji, Gulam A.
    Duong, Jimmy K.
    Schwartz, Gary K.
    Ivanova, Anastasia
    Lee, Shing M.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (03) : 477 - 494
  • [34] Dose-finding designs for cumulative toxicities using multiple constraints
    Lee, Shing M.
    Ursino, Moreno
    Cheung, Ying Kuen
    Zohar, Sarah
    BIOSTATISTICS, 2019, 20 (01) : 17 - 29
  • [35] Escalation, group and A+B designs for dose-finding trials
    Ivanova, Anastasia
    STATISTICS IN MEDICINE, 2006, 25 (21) : 3668 - 3678
  • [36] Optimal dose-finding designs with correlated continuous and discrete responses
    Fedorov, Valerii
    Wu, Yuehui
    Zhang, Rongmei
    STATISTICS IN MEDICINE, 2012, 31 (03) : 217 - 234
  • [37] Embracing model-based designs for dose-finding trials
    Sharon B Love
    Sarah Brown
    Christopher J Weir
    Chris Harbron
    Christina Yap
    Birgit Gaschler-Markefski
    James Matcham
    Louise Caffrey
    Christopher McKevitt
    Sally Clive
    Charlie Craddock
    James Spicer
    Victoria Cornelius
    British Journal of Cancer, 2017, 117 : 332 - 339
  • [38] Embracing model-based designs for dose-finding trials
    Love, Sharon B.
    Brown, Sarah
    Weir, Christopher J.
    Harbron, Chris
    Yap, Christina
    Gaschler-Markefski, Birgit
    Matcham, James
    Caffrey, Louise
    McKevitt, Christopher
    Clive, Sally
    Craddock, Charlie
    Spicer, James
    Cornelius, Victoria
    BRITISH JOURNAL OF CANCER, 2017, 117 (03) : 332 - 339
  • [39] A Unified Decision Framework for Phase I Dose-Finding Designs
    Yunshan Duan
    Shijie Yuan
    Yuan Ji
    Peter Mueller
    Statistics in Biosciences, 2024, 16 : 69 - 85
  • [40] A Unified Decision Framework for Phase I Dose-Finding Designs
    Duan, Yunshan
    Yuan, Shijie
    Ji, Yuan
    Mueller, Peter
    STATISTICS IN BIOSCIENCES, 2024, 16 (01) : 69 - 85